08 Sep 2026 Recon: FDA approves AZ’s breast cancer drug over negative adcomm vote; Novartis sees setbacks for drugs targeting cholesterol, myotonic dystrophy Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
03 Sep 2026 Recon: CBER official overruled Replimune melanoma drug rejection; AbbVie claims Phase 3 win for multiple myeloma drug Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
01 Sep 2026 Recon: Trump announces new pricing deals with midsize biotechs; Novartis pauses CAR-T trials after patient deaths Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
31 Aug 2026 Recon: FDA approves Protagonist and Takeda’s drug for rare blood cancer; Lilly to buy Merida for up to $2.88B Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
27 Aug 2026 Recon: FDA weighs new deputy commissioner posts; Trump set to reveal more MFN drug pricing deals Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
25 Aug 2026 Recon: FDA expands labels for J&J’s Imaavy, Jazz's Ziihera; Teva faces Turkish antitrust probe over patent moves Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
24 Aug 2026 Recon: FDA clears Roche, Lilly Alzheimer’s blood tests; Regenxbio gene therapy trial halted by FDA again Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
20 Aug 2026 Recon: FDA approves Ultragenyx gene therapy for glycogen storage disorder; Overton faces confirmation challenges Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
18 Aug 2026 Recon: FDA releases draft guidance on gen AI-enabled devices; Industry warns Germany must reform drug pricing Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
17 Aug 2026 Recon: FDA approves Zenbexus for multiple myeloma; NSAI seeks buyer for its MDR notified body business Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
